Details on our estimate changes, and new price target goes from $18 to $20 - Our estimate changes are relatively small; we see EPS above the guided range for the August quarter (management guided to a loss of $0.16 to $0.24, we see a loss of $0.13), and we see November quarter EPS at $0.08 vs. our prior $0.06. We'd emphasize that these are small changes, as we had already budgeted for healthy improvement in pricing and were already at the high end of company guidance for the current quarter. For our price target, we are raising our through-cycle EPS estimate from $1.65 to $1.85, based on continued softer DRAM capex - and we expect to be at this EPS run rate within 12 months. We see "through cycle" earnings at slightly above the midpoint of peak ($3.50) and trough ($0.00) EPS. Our price target is based on 11x this number, in line with where the stock has traded historically. We note that this is still well below replacement value, which we estimate to be $28.80.